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Abstract The purpose of this article is to describe the
current status and future perspectives of the Japan Breast
Cancer Research Group (JBCRG). The JBCRG was orga-
nized in 2002, with the following purpose: to plan and
promote clinical trials and basic research in breast cancer
domestically and multilaterally; to conduct research and
surveys on domestic and foreign information on medical
care for breast cancer and to diffuse and highlight such
information; to improve and promote clinical technologies
for breast cancer; to act as an intermediary to liaise and
strengthen alliances with affiliated organizations; and, to
contribute to the public welfare by improving outcomes in
breast cancer. The clinical trials are led by doctors/inves-
tigators in the JBCRG. And the purpose is to establish
standard treatment for patients and provide substantial
evidence. The JBCRG implements international collabo-
ration in some researches/studies. As of January 2012,
fourteen trials have been closed and nine are open to
recruitment.
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Introduction
The incidence of breast cancer in Japan has increased
yearly; thus, more attention has been given to breast cancer
treatment, among all cancers. In order to save as many
breast cancer patients as possible, and to improve their
quality of life (QOL), new diagnostic methods, treatments,
and prophylaxes for breast cancer should be developed.
The JBCRG shall carry out the following, to serve the
aforementioned purpose:
1. Basic and clinical research
2. Collection, analysis, and publication of information
3. Mutual exchange of information
4. Ordinary/extraordinary general meetings
5. Any other affairs required to accomplish the purpose
of the JBCRG
The JBCRG has conducted mainly phase II trials to give
answers to clinical questions, and now is planning to start
phase III ones to achieve clinical approval of new standard
therapies. The JBCRG is soliciting donations from orga-
nizations and individuals who wish to support its activities.
The JBCRG usually manages data quality by central
monitoring at data centers including the JBCRG Data
Center, which is located in the Kyoto Technoscience
Center, Kyoto; however, in some studies such as the SOLE
trial, the JBCRG conducted site visits for source document
verification.
As of January 2012, 243 doctors from 154 institutes are
registered as JBCRG members who are specialists from the
breast cancer treating hospitals around Japan. Also, the
JBCRG is a member of the Breast International Group
(BIG), which is an international breast cancer research
group. Tables 1 and 2 summarize the closed and ongoing
clinical trials, respectively.
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Neoadjuvant pharmacotherapy
The first clinical trial conducted by the JBCRG was
JBCRG-01, a phase II trial of preoperative systemic ther-
apy (PST) using fluorouracil, epirubicin, and cyclophos-
phamide (FEC) followed by docetaxel (Doc) in patients
with primary operable breast cancer [1–3]. Subsequently,
JBCRG-02 study was conducted using FEC followed by
Doc100 to investigate the safety and feasibility of 100 mg/
m2 Doc as PST. JBCRG-03 was a study to clarify the most
effective sequence of FEC and Doc75 [4]. From the results
of these studies, we defined new criteria of pathological
response to PST, quasi pathological complete response
(QpCR), total or near total disappearance of the invasive
tumor in the removed breast. QpCR following preoperative
chemotherapy predicts favorable disease-free survival
(DFS). HER2 overexpression and clinical response to FEC
predict QpCR [5, 6].
JBCRG-01
JBCRG-01 was started in 2002 [1–3]. This multicenter
phase II study examined the impact of pathological effect
on survival after preoperative chemotherapy in Japanese
women with early-stage breast cancer (ESBC). Prior to
surgery, patients received four cycles of FEC (fluorouracil
500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide
500 mg/m2 q3w) followed by four cycles of docetaxel
(75 mg/m2 q3w). The primary endpoint was 3-year DFS
stratified by the absence or presence of QpCR (absence of
invasive tumor or only focal residual tumor cells). Sec-
ondary endpoints were predictors for QpCR, clinical
response, breast conservation rate, and safety. Between
June 2002 and June 2004, 202 women were enrolled.
Among 191 assessable patients, 25 % achieved QpCR.
With 40 months median follow-up, 3-year DFS was esti-
mated at 91 % for all patients. The 3-year DFS for patients
Table 1 JBCRG trials closed/in follow-up
Trial Design No. of pts Primary endpoints Regimen Enrollment
start date
Neoadjuvant setting
1 Phase II 202 Clinical response, safety FEC100 q3w94 ? Doc75 q3w94 Jun 02
2 Phase II 31 Clinical response, safety FEC100 q3w94 ? Doc100 q3w94 Aug 04
20 Validation 19 Clinical response,
histological effects, safety
FEC100 q3w94 ? Doc100 q3w94 Dec 05
3 Phase II 130 Histological effects, safety Doc75 q3w94 ? FEC100 q3w94 Oct 05
5 Phase II 33 Response rates Doc75 q3w94 ? letrozole 12 (-18) w Sep 07
6 Phase II 40 Response rates Letrozole 12 (-18) w Sep 07
7 Phase II 40 Response rates Letrozole ? cyclophosphamide 24 w Oct 07
10 Randomized
phase II
180 Pathological CR rate (1) FEC94 ? TCH94, (2)
TCH94 ? FEC94, (3) TCH96
Jun 09
13 Phase II 40 Pathological CR rate Metronomic PCX 4 ? FEC94 Jan 10
Postoperative setting
4 (CREATE-X) Phase III 900 Disease-free survival Any preoperative systemic
therapy ± capecitabine
Feb 07
SOLE with BIG Phase III 4,800 Disease-free survival Intermittent or continuous letrozole Apr 10
8 ALTTO Phase III 140 Disease-free survival Lapatinib and/or trastuzumab Jul 07
Metastatic setting
M01 Phase I 6 MTD, DLT, RD CPT11 ? S1 Jul 06
M01 Phase II 37 Response rates,
clinical efficacy
CPT11 ? S1 Jul 06
M02 Phase II 50 Response rates Letrozole Nov 06
Cohort study
C01 Cohort 1,500 Disease-free survival Trastuzumab Sep 07
Data correct as of 31 March 2012
CR complete response, MTD maximum tolerated dose, DLT dose limiting toxicity, RD recommended dose, FEC 5-fluorouracil ? epirubicin ?
cyclophosphamide, Doc docetaxel, TCH docetaxel ? cyclophosphamide ? trastuzumab, PCX paclitaxel ? cyclophosphamide ? capecitabine
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with QpCR was 98 vs. 89 % for those without QpCR
(hazard ratio 0.38 [95 % confidence interval 0.09–0.84],
P = 0.0134). HER2 status and response to FEC were
independent predictors of QpCR. The overall clinical
response rate was 75 %; 85 % of patients achieved breast
conservation. Grade 3/4 neutropenia was the most common
adverse event, observed in 44 and 35 % of patients during
FEC and docetaxel treatment, respectively. Treatment-
related side effects were manageable; there were no treat-
ment-related fatalities.
JBCRG-02
The JBCRG-02 study was conducted to evaluate the safety
and clinical and histologic effects of primary systemic
chemotherapy using FEC followed by docetaxel in primary
breast cancer. The primary endpoints were safety and clin-
ical and histologic effects. Secondary endpoints were breast-
conserving rate and DFS. Fluorouracil 500 mg/m2, epiru-
bicin 100 mg/m2, and cyclophosphamide 500 mg/m2, q3w
94 cycles, were followed by docetaxel 100 mg/m2, q3w 94
cycles, as primary systemic chemotherapy. Among patients
receiving this regimen, 19.5 % experienced a pathological
complete response and 9.7 % had a near pathological
complete response, resulting in a QpCR of 29.2 %.
JBCRG-03
JBCRG-03 was a multicenter, open-label, single-arm,
phase II study assessing the efficacy of a neoadjuvant
chemotherapy with docetaxel (75 mg/m2 q3w) followed by
5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and
cyclophosphamide 500 mg/m2 q3w in patients with ESBC
[4]. The primary endpoint was the pathological complete
response (pCR) rate defined for the breast alone, assessed
by a central review committee. Secondary endpoints
included clinical response and safety. Of the 132 patients
assessable for pathologic response, 23 % experienced a
pCR and 6 % had a near pathological complete response
(few remaining cancer cells), resulting in a QpCR of 29 %.
Clinical response rate following the initial docetaxel regi-
men was 64 %. The overall clinical response rate was
79 %. Breast-conserving surgery was performed in 79 % of
patients. More patients with triple-negative disease expe-
rienced a pCR (14/29, 48 %) versus those with other
molecular subtypes. The safety profile was acceptable.
Oncotype DX
The 21-gene signature has been intensively studied and
incorporated into major guidelines for treatment decision in
early breast cancer. However, it remains to be examined
whether this system is applicable to Asian populations.
Retrospective analysis
Toi et al. [7] were the first report to show that the 21-gene
signature has value in providing prognostic information in
Asian populations with estrogen receptor (ER)-positive,
lymph node (LN)-negative breast cancer. A total of 325
tumor tissues were collected from ER-positive primary
breast cancer patients who had undergone surgery and were
Table 2 JBCRG trials open to recruitment





195 Histological response TC96, FEC93 ? TC93,TC93 ? FEC93 Sep 09
11CPA Phase II 55 Response rates Letrozole ± low dose cyclophosphamide Oct 10




15 Phase II 30 Pharmacokinetics Toremifene Mar 09
SUPREMO with IBCSG Phase III 3,700 Overall survival Chest wall radiation Jul 09
Metastatic setting
12 Phase II 200 CYP2D6 and
pharmacokinetics
Tamoxifen and toremifene Jan 10
Cohort study
C02 Cohort 100 Progression-free survival Trastuzumab Jul 09
Data correct as of 31 March 2012
TC docetaxel ? cyclophosphamide, FEC 5-fluorouracil ? epirubicin ? cyclophosphamide
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treated with tamoxifen between 1992 and 1998. The tissues
were analyzed for the 21-gene signature, and the patients
were classified into groups of low, intermediate, or high
risk on the basis of the recurrence score. A total of 280
patients were eligible, with adequate reverse transcription
polymerase chain reaction profiles for the recurrence score.
Of those, 200 and 80 patients had LN-negative and
LN-positive disease, respectively. The proportions of
LN-negative patients categorized as being at low, inter-
mediate, or high risk were 48, 20, and 33 %, respectively.
In LN-negative patients, the Kaplan–Meier estimates of the
distant recurrence rate at 10 years were 3.3 % (95 % CI
1.1–10.0 %), 0 %, and 24.8 % (95 % CI 15.7–37.8 %) for
those in the low-risk, intermediate-risk, and high-risk
groups, respectively. The risk of distant recurrence in the
low-risk group was significantly lower than that in the
high-risk group when the entire Kaplan–Meier plots were
compared (P \ 0.001, log-rank test). There was a signifi-
cant difference for overall survival between the low-risk
and the high-risk groups (P = 0.008, log-rank test).
Economic evaluation
JBCRG-TR03
This study evaluates the cost-effectiveness of two scenarios
designed to include the assay into Japan’s social health
insurance benefit package: one for LN-, ER?, ESBC and
another for LN±, ER?, ESBC [8]. An economic decision
tree and Markov model under Japan’s health system from
the societal perspective is constructed with new evidence
from the Japanese validation study. Incremental cost-
effectiveness ratios are estimated as ¥384,828 (US$3,848)
per quality-adjusted life year (QALY) for the LN- sce-
nario and ¥568,533 (US$5,685) per QALY for the LN±
scenario. Both estimates are not more than the suggested
social willingness-to-pay for one QALY gain from an
innovative medical intervention in Japan, ¥5,000,000/
QALY (US$50,000/QALY). Sensitivity analyses show that
this result is plausibly robust, because the incremental cost
effectiveness ratios (ICERs) do not exceed the threshold
despite various changes of assumptions made and values
employed. Therefore, the inclusion of the assay in Japan’s
social health insurance benefit package for not only LN-
diseases but also LN? diseases is cost-effective. Such a
decision can be justifiable as an efficient use of finite
resources for health care.
Toxicity
Steroids and H(2) blockers are commonly used as sup-
portive care for taxane-containing chemotherapy, but they
also affect docetaxel’s primary metabolizer, cytochrome
P(450) 3A4. Kawaguchi et al. [9] performed a retrospective
observational study to better understand the effects of these
compounds on docetaxel-induced skin toxicities, specifi-
cally hand-foot syndrome (HFS) and facial erythema (FE),
a relationship that is currently poorly understood. Member
institutions of the JBCRG were invited to complete a
questionnaire on the occurrence of grade 2 or higher HFS
and FE among patients treated between April 2007 and
March 2008 with docetaxel as an adjuvant or neoadjuvant
chemotherapeutic treatment for breast cancer. We obtained
data for 993 patients from 20 institutions. Twenty percent
received H(2) blockers, and all patients received dexa-
methasone. Univariate and multivariate analyses revealed
that H(2) blockers are associated with a significantly higher
incidence of both HFS and FE. The incidence of FE was
significantly higher for the docetaxel ? cyclophosphamide
(TC) regimen than for non-TC regimens combined.
Dexamethasone usage did not affect the incidence of either
HFS or FE. In conclusion, the use of H(2) blockers as
premedication in breast cancer patients receiving docetaxel
significantly increases the risk of both HFS and FE.
International study
The JBCRG is a member of the international breast cancer
research group BIG. The JBCRG has joined in with several
international clinical studies.
JBCRG-04 (CREATE-X)
This study aims to investigate the efficacy and safety of
capecitabine, as a postoperative adjuvant chemotherapy,
for breast cancer patients who were pathologically dem-
onstrated to have residual cancer cells after the preopera-
tive chemotherapy. In addition, the cost-effectiveness of
capecitabine is to be investigated. The primary objective is
DFS and secondary ones are overall survival, safety, and
cost-effectiveness. Eligible patients had stage I-IIIB at the
first diagnosis (curable breast cancer) and were non-pCR
after preoperative chemotherapy including at least two
cycles anthracycline agents; that is, they were confirmed
pathologically by surgical and/or histological tests to have
residual cancer cells. The patients had also been confirmed
to be HER2 negative.
JBCRG-08 (ALTTO)
JBCRG-08 was a randomized, multicenter, open-label,
phase III study of adjuvant lapatinib, trastuzumab, their
sequence, and their combination in patients with HER2/
ErbB2-positive primary breast cancer (BIG 2-06/N063D/
EGF 106708.). The objective of this study was to compare
DFS in patients with HER2 overexpressing and/or amplified
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breast cancer randomized to trastuzumab for 1 year versus
lapatinib for 1 year versus trastuzumab (12 weeks) fol-
lowed by a 6-week treatment-free interval followed by la-
patinib (34 weeks) versus trastuzumab in combination with
lapatinib for 1 year. Endpoints were DFS, overall survival
(OS), time to recurrence (TTR), time to distant recurrence
(TTDR), safety and tolerability, cumulative incidence of
brain metastases as the first site of breast cancer recurrence,
presence or absence of cMyc gene amplification, expression
levels of PTEN, and presence or absence of p95 HER2
domain. Trial periods were between July 2007 and February
2011 (registration, 2 years; follow-up study, 5 years). Tar-
get sample size was 140 from 15 institutions.
SOLE trial
SOLE trial is a phase III trial evaluating the role of con-
tinuous letrozole versus intermittent letrozole following
4–6 years of prior adjuvant endocrine therapy for post-
menopausal women with hormone receptor-positive, node-
positive ESBC. The JBCRG is collaborating with the
International Breast Cancer Study Group (IBCSG) on this
trial. A total of 4,800 patients are expected to be enrolled in
this study. The primary endpoint is DFS, and secondary
ones are OS, distant DFS, breast cancer-free interval, sites
of first failure, second (non-breast) malignancies, deaths
without prior cancer events, and adverse events.
SUPREMO trial
The SUPREMO trial is a randomized phase III trial assess-
ing the role of chest wall irradiation in women with inter-
mediate-risk breast cancer following mastectomy conducted
by BIG. Postoperative radiotherapy is routinely given to
patients at higher risk of recurrence with 4 or more LNs or
large tumor(s). In patients with less than 4 LNs under the
armpit involved by cancer or with no LNs involved but other
features of the cancer that increase the risk of recurrence, it is
not clear whether postoperative radiotherapy is needed.
Eligibility criteria are a postoperative breast cancer patient
who has had a mastectomy, and who has an intermediate risk
of the cancer returning. An intermediate risk is diagnosed
when there are less than 4 LNs under the armpit involved by
cancer or there are no LNs involved, but there are other
features of the cancer that mean it is more likely to come
back. The trial will involve 1,600 women.
Conclusion
The JBCRG was founded in order to perform good-quality
multicenter studies, and related clinical trials in close
liaison with research institutions in other countries and
regions, as well as in Japan. The JBCRG has performed a
variety of studies, including primary pharmacotherapy,
pharmacotherapy for recurrent breast cancer, clinical trials
on postoperative pharmacotherapy, prediction of prognosis
in hormone receptor-positive breast cancer, and prediction
of the effect of chemotherapeutic drugs. The JBCRG has
reported a number of outcomes to academic societies and
in journals, and has obtained a good reputation. The inci-
dence of breast cancer in Japan has increased yearly; thus,
more attention has been given to breast cancer treatment,
among all cancers. In order to save as many breast cancer
patients as possible, and to improve their QOL, we will
develop new diagnostic methods, treatments, and prophy-
laxes for breast cancer.
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